NCT02253914View on ClinicalTrials.gov

Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of BILR 355 BS Plus Low Dose Ritonavir in HIV-uninfected Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

December 31, 2004

Conditions
Healthy
Interventions
DRUG

BILR 355 BS, solution

DRUG

BILR 355 BS, tablet

DRUG

Ritonavir

DRUG

Placebo

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY